and Media

News Releases

Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
Portola and WTD Aim to Make VTE Protocol and Prevention a Priority Patient Safety Issue in Hospitals Across the United States

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) announced today that it will be serving as a global partner for World Thrombosis Day to help raise awareness of the incidence, risks and potentially life-threatening complications of thrombosis.

World Thrombosis Day, observed on October 13, is an annual event led by the International Society on Thrombosis and Haemostasis (ISTH) and is carried out by more than 1,000 organizations representing 85 countries worldwide. The focus for World Thrombosis Day 2017 is Know Thrombosis, which encourages healthcare professionals, key decision makers and the public to know the risk factors, signs and symptoms of the condition.

“VTE is preventable with the proper prevention and treatment procedures. We are committed to our partnership with World Thrombosis Day and ISTH to raise awareness to help reduce death and disability caused by this condition,” said John Curnutte, MD, PhD, Executive Vice President, Research and Development at Portola.  “We encourage the healthcare community to join the World Thrombosis Day movement to make VTE prevention a priority.”

Venous thromboembolism (VTE), also known as a blood clot, is a leading cause of death and disability worldwide. Patients hospitalized for serious, common medical conditions (i.e., acutely ill medical patients) are at increased risk for VTE. In the G7 countries, an estimated 24 million acutely ill medical patients are hospitalized each year and are at risk of VTE, either while in the hospital or following discharge. More than one million VTE events and 150,000 VTE-related deaths occur annually in acutely ill medical patients in the G7 countries, despite the standard use of injectable enoxaparin and other heparins in the hospital. More than half of VTE events occur after patients are discharged from the hospital.

“Our partners are critical in helping to expand the reach of World Thrombosis Day and we are proud to partner with Portola for the third straight year,” said Gary Raskob, PhD, Chairman of the World Thrombosis Day Steering Committee; Dean, College of Public Health, University of Oklahoma Health Sciences Center. “WTD is a timely opportunity to discuss, update or establish your organization’s VTE policy. Preventing clots is a patient safety issue and should be a standard of care for all hospitalized patients. Policies should engage all staff involved in patient care and strive for high compliance.”

Recent advances in the field of thrombosis have led to the development of novel oral anticoagulants (NOACs) to prevent and treat VTEs. NOACs are predominantly comprised of a class of drugs called Factor Xa inhibitors, which are indicated to prevent stroke and blood clots in people with atrial fibrillation; to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE); and to prevent DVT, which may lead to PE, following hip or knee replacement surgery. In the United States, an estimated 2.5 million people will be treated with a Factor Xa inhibitor this year. The number of patients on Factor Xa inhibitors is currently growing at a rapid rate of approximately 45 percent year-over-year.

About World Thrombosis Day
Launched in 2014 and held annually on October 13, World Thrombosis Day (WTD) aims to increase public, healthcare professional and health care systems’ awareness of thrombosis and, ultimately, to reduce deaths and disabilities from thromboembolic disease through a greater awareness of its causes, risk factors, signs and symptoms, and evidence-based prevention and treatment. WTD’s mission supports the World Health Assembly's global target of reducing premature deaths by non-communicable disease by 25 percent by 2025, as well as the WHO global action plan for the prevention and control of non-communicable diseases in the 2013-2020 timeframe. Portola Pharmaceuticals and many others are proud sponsors of WTD 2017. Visit for more information.

About the ISTH
Founded in 1969, the International Society on Thrombosis and Haemostasis (ISTH) is the leading worldwide not-for-profit organization dedicated to advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The ISTH is an international membership organization with nearly 4,000 clinicians, researchers and educators working together to improve the lives of patients in more than 94 countries around the world. Among its highly regarded activities and initiatives are education and standardization programs, research activities, meetings and conferences, peer-reviewed publications and expert committees. Visit ISTH online at

About Portola Pharmaceuticals, Inc. ®
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for AndexXa™ (andexanet alfa), a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit and follow the Company on Twitter @Portola_Pharma. 

Forward-looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, cerdulatinib’s potential as a treatment for hematologic cancers and the potential of Portola’s other product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: failure to obtain FDA and/or EMA approval for one or more of our product candidates, regulatory developments in the United States and foreign countries; our expectation that we will incur losses for the foreseeable future and will need additional funds to finance our operations; the accuracy of our estimates regarding our ability to initiate and/or complete our clinical trials and the timing and expense of these trials; the results of our clinical trials related to the efficacy and safety of our product candidates; our potential inability to manufacture our product candidates on a commercial scale in a timely or cost-efficient manner; the accuracy of our estimates regarding expenses and capital requirements; our ability to successfully build a hospital-based sales force and commercial infrastructure; our ability to obtain and maintain intellectual property protection for our product candidates; and our ability to retain key scientific or management personnel. These and other risks and uncertainties are described more fully in our most recent filings with the Securities and Exchange Commission, including our most recent quarterly report on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contact:                              
Michele Mantynen
Portola Pharmaceuticals

Media Contact:
Patrick Ryan
W2O Group

Primary Logo

Portola Pharmaceuticals, Inc.